---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-005246"
form_type: "8-K"
ticker: "TOI"
cik: "0001799191"
company_name: "Oncology Institute, Inc."
filed_at: "2022-03-07T23:59:59+00:00"
generated_at: "2026-06-27T01:14:16.281098+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# TOI promotes Dr. Daniel Virnich to President and Dr. Matthew Miller to COO

## Summary
- Dr. Daniel Virnich promoted from COO to President, effective March 15, 2022.
- Dr. Matthew Miller promoted from Chief Administrative Officer to COO, effective same date.
- Board approved RSU/option grants: CEO Hively $678K RSU + $1.38M options; Virnich $263K RSU + $533K options; Dalgleish $201K RSU + $407K options.
- Updated 2021 compensation: Hively $11.6M, Virnich $7.6M, Dalgleish $4.8M total pay.

## SEC filing metadata
- accession: 0001628280-22-005246
- form_type: 8-K
- ticker: TOI
- cik: 0001799191
- company_name: Oncology Institute, Inc.
- filed_at: 2022-03-07T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799191/000162828022005246/0001628280-22-005246-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799191/000162828022005246/toi-20220302.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-005246
- JSON: https://secwatch.observer/filing/0001628280-22-005246.json
- Plain text: https://secwatch.observer/filing/0001628280-22-005246.txt

## Key facts
- Executive change
  Dr. Daniel Virnich changed role as President at Oncology Institute, Inc..
  - Action: promoted
  - Role: President
  source text: On March 2, 2022, the Board of Directors of The Oncology Institute, Inc. (the "Company") promoted Dr. Daniel Virnich to serve as President of the Company, effective as of March 15, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1799191/000162828022005246/0001628280-22-005246-index.htm
- Executive change
  Dr. Matthew Miller changed role as Chief Operating Officer at Oncology Institute, Inc..
  - Action: promoted
  - Role: Chief Operating Officer
  source text: On March 2, 2022, the Board of Directors of the Company promoted Dr. Matthew Miller to succeed Dr. Virnich as Chief Operating Officer, effective as of March 15, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1799191/000162828022005246/0001628280-22-005246-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.